Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis

Mayerle, Julia; Kalthoff, Holger; Reszka, Regina; Kamlage, Beate; Peter, Erik; Schniewind, Bodo; Maldonado, Sandra González; Pilarsky, Christian; Heidecke, Claus–Dieter; Schatz, Philipp; Distler, Marius; Scheiber, Jonas A.; Mahajan, Ujjwal Mukund; Weiß, Frank Ulrich; Grützmann, Robert; Lerch, Markus M.

doi:10.1136/gutjnl-2016-312432

Cited by 225 publications

(224 citation statements)

References 53 publications

Supporting

Mentioning

211

Contrasting

Unclassified

Order By: Relevance

“…It has been found to be 85% sensitive, 94.9% specific, and has a diagnostic accuracy of 90% to distinguish PDAC from CP. Its negative predictive value is 99.9%, and false negative rate is only 11% [63].…”

Section: Laboratory Investigationsmentioning

confidence: 92%

Diagnosis and Management of Pancreatic Adenocarcinoma in the Background of Chronic Pancreatitis: Core Issues

Narkhede

Desai

Prasad

et al. 2019

Dig Dis

View full text Add to dashboard Cite

Background: The incidence of pancreatic adenocarcinoma (PDAC) in patients with chronic pancreatitis (CP) is as high as 5%. It is a commonly encountered diagnostic challenge in patients with CP on long-term follow-up. Summary: This review consolidates the existing literature on assessment of PDAC in background of CP, its evaluation through the available investigations, surgical management, and prognostication. Recent change in symptomatology of an otherwise stable CP should raise a suspicion of malignancy. Endoscopic ultrasound (EUS) is more specific and sensitive in establishing the diagnosis of PDAC compared to cross-sectional imaging (computed tomography/magnetic resonance imaging). Intraoperative assessment with careful palpation coupled with careful clinical judgment helps in differentiating between an inflammatory mass and pancreatic cancer. Confirmation can be obtained with either preoperative EUS-guided fine needle cytology/core biopsy or intraoperative core biopsy under ultrasound guidance. However, despite complete evaluation with above options, 1–6% patients often show malignancy on final histopathological examination. Key Messages: Diagnosis of PDAC in CP needs a high index of suspicion. Cross-sectional imaging has poor negative predictive value. CA 19-9 with MUC5AC combination may become an ideal investigation. EUS with core biopsy/frozen section has a good sensitivity and specificity and low false negative results. Complete radical resection should be the aim to get long-term survival.

show abstract

Section: Laboratory Investigationsmentioning

confidence: 92%

Diagnosis and Management of Pancreatic Adenocarcinoma in the Background of Chronic Pancreatitis: Core Issues

Narkhede

Desai

Prasad

et al. 2019

Dig Dis

View full text Add to dashboard Cite

show abstract

“…Metabolic biomarkers were also used to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis . In a case‐control metabolomics study performed using both GC‐MS and LC‐MS, a biomarker signature comprised of nine metabolites and additionally carbohydrate antigen 19‐9 was identified to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis with a sensitivity of 89.9% and a specificity of 91.3%, respectively.…”

Section: Applications Of Metabolomics In Clinical Pharmacologymentioning

confidence: 99%

Emerging Applications of Metabolomics in Clinical Pharmacology

Pang

Wang

2019

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

Metabolic disturbances have been associated with many human diseases, including cancer, diabetes, and cardiovascular disease. Metabolomics, a rapidly growing member of the –omics family, investigates cellular metabolism by quantifying metabolites on a large scale and provides a link between metabolic pathways and the upstream genome that governs them. With the advances in analytical technologies, metabolomics is becoming a powerful tool for identifying diagnostic biomarkers of diseases, elucidating the pathological mechanisms, discovering novel drug targets, predicting drug responses, interpreting the mechanisms of drug action, as well as enabling precision treatment of patients. In this review, we highlight the recent advances of technologies and methodologies in metabolomics and their applications to the field of clinical pharmacology. Recent publications from 2013 to 2018 are covered in the review, and current challenges and potential future directions in the field are also discussed.

show abstract

“…A recent study by Mayerle et al . used both untargeted and targeted MS‐based approaches including lipidomics and showed that PDAC patients could be distinguished from CP patients, as well as from healthy controls . Using a case–control design, 914 subjects with PDAC ( n = 271), CP ( n = 282), liver cirrhosis ( n = 100), and healthy and non‐pancreatic disease controls ( n = 261) were recruited in three consecutive studies.…”

Section: Blood‐based Biomarkersmentioning

confidence: 99%

A review of lifestyle, metabolic risk factors, and blood‐based biomarkers for early diagnosis of pancreatic ductal adenocarcinoma

Pang

Holmes

Chen

et al. 2019

J of Gastro and Hepatol

View full text Add to dashboard Cite

We aimed to review the epidemiologic literature examining lifestyle and metabolic risk factors, and blood‐based biomarkers including multi‐omics (genomics, proteomics, and metabolomics) and to discuss how these predictive markers can inform early diagnosis of pancreatic ductal adenocarcinoma (PDAC). A search of the PubMed database was conducted in June 2018 to review epidemiologic studies of (i) lifestyle and metabolic risk factors for PDAC, genome‐wide association studies, and risk prediction models incorporating these factors and (ii) blood‐based biomarkers for PDAC (conventional diagnostic markers, metabolomics, and proteomics). Prospective cohort studies have reported at least 20 possible risk factors for PDAC, including smoking, heavy alcohol drinking, adiposity, diabetes, and pancreatitis, but the relative risks and population attributable fractions of individual risk factors are small (mostly < 10%). High‐throughput technologies have continued to yield promising genetic, metabolic, and protein biomarkers in addition to conventional biomarkers such as carbohydrate antigen 19‐9. Nonetheless, most studies have utilized a hospital‐based case–control design, and the diagnostic accuracy is low in studies that collected pre‐diagnostic samples. Risk prediction models incorporating lifestyle and metabolic factors as well as other clinical parameters have shown good discrimination and calibration. Combination of traditional risk factors, genomics, and blood‐based biomarkers can help identify high‐risk populations and inform clinical decisions. Multi‐omics investigations can provide valuable insights into disease etiology, but prospective cohort studies that collect pre‐diagnostic samples and validation in independent studies are warranted.

show abstract

Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis

Cited by 225 publications

References 53 publications

Diagnosis and Management of Pancreatic Adenocarcinoma in the Background of Chronic Pancreatitis: Core Issues

Diagnosis and Management of Pancreatic Adenocarcinoma in the Background of Chronic Pancreatitis: Core Issues

Emerging Applications of Metabolomics in Clinical Pharmacology

A review of lifestyle, metabolic risk factors, and blood‐based biomarkers for early diagnosis of pancreatic ductal adenocarcinoma

Contact Info

Product

Resources

About